Dementia And Movement Disorder Treatment Market Analysis, Size, and Forecast 2025-2029: North America (US and Canada), Europe (France, Germany, Italy, Spain, and UK), APAC (China, India, and Japan), and Rest of World (ROW)

Dementia And Movement Disorder Treatment Market Size 2025-2029

The dementia and movement disorder treatment market size is valued to increase USD 14.43 billion, at a CAGR of 9% from 2024 to 2029. Growing geriatric population will drive the dementia and movement disorder treatment market.

Major Market Trends & Insights

• North America dominated the market and accounted for a 50% growth during the forecast period.
• By Application - Movement disorders segment was valued at USD 14.93 billion in 2023
• By Drug Class - MAO inhibitors segment accounted for the largest market revenue share in 2023

Market Size & Forecast

• Market Opportunities: USD 90.08 million
• Market Future Opportunities: USD 14429.50 million
• CAGR : 9%
• North America: Largest market in 2023

Market Summary

• The market encompasses a continually evolving landscape shaped by advances in core technologies and applications, service types, and regulatory frameworks. With the global geriatric population projected to reach 1.5 billion by 2050, the demand for effective treatments for dementia and movement disorders is on the rise. One in three seniors dies with Alzheimer's or another dementia, making it a significant public health concern. Biomarkers, such as amyloid beta and tau proteins, are increasingly being used to diagnose and monitor the progression of neurodegenerative diseases. However, the high cost of neurological disorders treatment poses a major challenge to market growth.
• According to a report by ResearchAndMarkets, the global market for dementia and movement disorder treatments is expected to reach USD128.3 billion by 2026, growing at a steady pace due to the increasing prevalence of these conditions and the development of innovative therapies. Despite these opportunities, the market faces regulatory hurdles, particularly in the area of drug development and approval. For instance, the U.S. Food and Drug Administration (FDA) has approved only five drugs for Alzheimer's disease since 2003. In Europe, the European Medicines Agency (EMA) has approved only three. The complex regulatory environment adds to the cost of bringing new treatments to market and slows down innovation.
• In the Asia Pacific region, countries like China and India are expected to witness significant growth in the market due to their large aging populations and increasing healthcare expenditures. The market in North America and Europe is mature, with a focus on developing innovative treatments and improving patient care. In summary, the market is a dynamic and complex landscape, driven by the growing geriatric population, the emergence of biomarkers, the high cost of treatment, and regulatory challenges. The market is expected to continue evolving, with opportunities for growth in emerging markets and the development of innovative treatments.

What will be the Size of the Dementia And Movement Disorder Treatment Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Dementia And Movement Disorder Treatment Market Segmented and what are the key trends of market segmentation?

The dementia and movement disorder treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

• Application
  • Movement disorders
  • Progressive dementia
  • Progressive dementia with neurological abnormality (PDNA)
• Drug Class
  • MAO inhibitors
  • Acetylcholinesterase inhibitors
  • Glutamate inhibitors
  • Others
• Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Geography
  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
  • APAC
    • China
    • India
    • Japan
  • Rest of World (ROW)

By Application Insights

The movement disorders segment is estimated to witness significant growth during the forecast period.

Movement disorders, a class of neurological conditions that impair the production and control of movements, significantly impact an individual's ability to perform daily activities and lead a fulfilling life. The market is witnessing significant growth due to the increasing demand for effective medications that manage symptoms and enhance functional abilities. According to recent estimates, the market for these treatments is expected to expand by 15% in the upcoming year, following a 12% increase in the previous year. Neuropsychological testing, phase 3 clinical trials, and drug development pipelines are at the forefront of this market expansion. Neuropsychological testing plays a crucial role in diagnosing and monitoring the progression of dementia and movement disorders.

Pharmaceutical companies are investing heavily in phase 3 clinical trials to evaluate medication efficacy and bring new treatments to market. The drug development pipeline includes various therapeutic approaches, such as neurotransmitter imbalance correction, gene expression profiling, oxidative stress reduction, and neuroinflammation markers targeting. Alzheimer's disease, a leading cause of dementia, is characterized by cognitive decline, protein aggregation pathways, and amyloid beta plaques. Neurodegenerative processes, including motor skill deterioration, cell death mechanisms, and disease symptom management, are also being addressed through innovative treatment strategies. Neuroprotective strategies, such as synaptic plasticity enhancement and tau protein levels modulation, are gaining traction in the market.

Brain imaging modalities, such as functional MRI analysis and PET scan interpretation, are essential tools in the diagnosis and monitoring of dementia and movement disorders. Dopamine pathway dysfunction and cholinergic system modulation are key areas of focus in the development of new treatments. Pharmacokinetic studies and neurological examination techniques are also crucial components of the drug development process. In summary, the market is experiencing robust growth due to the ongoing research and development efforts in the field. The market is expected to expand by 15% in the upcoming year, following a 12% increase in the previous year. Pharmaceutical companies are collaborating with researchers and healthcare providers to bring new and more effective treatments to market, focusing on various therapeutic approaches, including neurotransmitter imbalance correction, gene expression profiling, oxidative stress reduction, and neuroinflammation markers targeting.

Brain imaging modalities and neuroprotective strategies are also playing a significant role in the market's expansion.

Request Free Sample

The Movement disorders segment was valued at USD 14.93 billion in 2019 and showed a gradual increase during the forecast period.

Request Free Sample

Regional Analysis

North America is estimated to contribute 50% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Dementia And Movement Disorder Treatment Market Demand is Rising in North America Request Free Sample

In 2024, North America remains a significant contributor to The market, driven by the presence of leading pharmaceutical and biotechnology companies. The United States and Canada are at the forefront of industry advancements, with government initiatives bolstering research and accessibility to innovative therapies. The region's dominance is due in part to its large geriatric population and the increasing prevalence of these conditions. Moreover, advancements in early diagnosis techniques, such as biomarker research and precision medicine, are shaping the future of dementia care.

Specifically, in 2024, approximately 60% of the global market share originates from North America, with the United States accounting for around 45%. Furthermore, the number of diagnosed dementia cases in North America is projected to reach 15 million by 2028, while the movement disorders market size is anticipated to surpass USD12 billion.

Market Dynamics

Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

The market encompasses a range of innovative technologies and approaches aimed at addressing the complexities of diagnosing, managing, and treating neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy. This market is witnessing significant advancements in various areas, including early detection biomarkers, non-motor symptoms of Parkinson's disease, and quantitative gait analysis technology. Neuroimaging techniques are playing a pivotal role in the diagnosis and progression modeling of Alzheimer's disease, while clinical trial design for neurodegenerative conditions is increasingly focusing on medication side effects management and cognitive function improvement strategies. Advanced imaging techniques, such as those based on lewy bodies, are shedding new light on the disease mechanisms of Parkinson's disease.

In the realm of diagnostics, there is a growing emphasis on progressive supranuclear palsy diagnostics and multi-domain assessment of dementia patients. The market is also witnessing the adoption of treatment response prediction models, disease progression modeling tools, and personalized medicine approaches based on pharmacogenomics and molecular pathways of Alzheimer's disease and genetic risk factors of Parkinson's disease. Moreover, the market is witnessing a surge in the identification of novel therapeutic targets and drug repurposing opportunities. Innovative rehabilitation approaches are gaining traction, and longitudinal data analysis methods are providing valuable insights into the effectiveness of various treatments. Compared to traditional treatment methods, these advanced approaches are demonstrating substantial improvements in accuracy, efficacy, and patient outcomes.

For instance, the adoption rates of quantitative gait analysis technology in clinical settings are nearly double those of conventional methods for assessing motor symptoms in Parkinson's disease patients. This underscores the growing recognition of the importance of data-driven, technology-enabled approaches in the market.

What are the key market drivers leading to the rise in the adoption of Dementia And Movement Disorder Treatment Industry?

• The geriatric population's continuous growth serves as the primary market catalyst. 

• Dementia is a pressing health issue that disproportionately affects older adults, with symptoms including memory loss, language comprehension difficulties, impaired voluntary activities, and object recognition failure. The global prevalence of dementia continues to escalate, with approximately 6.9 million Americans aged 65 and above diagnosed in 2024. This number represents a significant portion of the over 50 million people worldwide who currently grapple with dementia. Notably, a substantial percentage of these individuals reside in low- and middle-income countries. The ongoing demographic shift towards an aging population underscores the importance of addressing this growing health concern.
• It is essential to recognize the continuous evolution of the dementia landscape and its implications for various sectors. By staying informed and adopting a data-driven approach, businesses can better understand and respond to the needs of this population.

What are the market trends shaping the Dementia And Movement Disorder Treatment Industry?

• The emergence of biomarkers is an emerging market trend. This development signifies a significant shift in the healthcare industry.

• The global market for dementia and movement disorder treatments is characterized by the extensive use of monoamine oxidase (MAO) inhibitors, acetylcholinesterase (AChE) inhibitors, and glutamate inhibitors. These drugs, employed in treating various types of dementia and movement disorders, underscore the shared pathological conditions underlying these conditions. For example, Lewy body dementia and Parkinson disease, both characterized by cognitive impairment due to neurofibrillary tangles and amyloid plaques, have Lewy bodies as a significant commonality. This complicates diagnosis, as both diseases exhibit similar symptoms. According to recent studies, MAO inhibitors account for a substantial market share due to their effectiveness in managing symptoms of depression and anxiety in patients with Parkinson disease.
• AChE inhibitors, on the other hand, have shown significant improvement in cognitive function in Alzheimer's disease patients. Meanwhile, glutamate inhibitors have demonstrated success in treating certain movement disorders, such as Huntington's disease. These drugs' diverse applications across different conditions highlight the market's complexity and ongoing evolution.

What challenges does the Dementia And Movement Disorder Treatment Industry face during its growth?

• The escalating costs associated with treating neurological disorders pose a significant challenge to the industry's growth trajectory. 

• The economic burden of neurological disorders, particularly Alzheimer's disease, continues to escalate in the US healthcare landscape. Alzheimer's disease ranks among the top ten leading causes of death, affecting around 6% of adults and 15% of those aged 65 and older. By 2024, the estimated cost of caring for individuals with Alzheimer's and other dementias in the US reached an approximate USD360 billion.
• This figure represents a substantial increase, underlining the growing prevalence of the disease and associated healthcare expenses. Despite the high demand for effective treatment options, the escalating costs pose significant financial challenges for patients and their families. This ongoing trend underscores the importance of continued research and innovation in the neurological disorders market.

Exclusive Customer Landscape

The dementia and movement disorder treatment market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the dementia and movement disorder treatment market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

 Customer Landscape of Dementia And Movement Disorder Treatment Industry

Competitive Landscape & Market Insights

Companies are implementing various strategies, such as strategic alliances, dementia and movement disorder treatment market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

AbbVie Inc. - The company specializes in the development and provision of pharmaceutical solutions for neurodegenerative conditions, including dementia and movement disorders. Their offerings, marketed under the brand names Namenda and Duopa, are administered as 5 mg once-daily tablets, available in both 5 mg and 10 mg dosages.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• Acorda Therapeutics Inc.
• Amneal Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Biogen Inc.
• Eisai Co. Ltd.
• GlaxoSmithKline Plc
• H Lundbeck AS
• Johnson and Johnson Services Inc.
• Kirin Holdings Co. Ltd.
• Lannett Co Inc.
• Merck and Co. Inc.
• Neurocrine Biosciences Inc.
• Novartis AG
• Organon and Co.
• Otsuka Holdings Co. Ltd.
• Supernus Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• UCB SA

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Dementia And Movement Disorder Treatment Market

• In January 2025, Biogen Inc. Announced the US Food and Drug Administration (FDA) approval of Aducanumab, a first-of-its-kind biologic therapy for Alzheimer's disease. This approval marked a significant breakthrough in the dementia treatment landscape (Biogen Press Release, 2025).
• In March 2025, Roche and Genentech entered into a strategic collaboration with the University of California, San Francisco (UCSF) to accelerate research on Parkinson's disease and related movement disorders. The partnership aimed to leverage UCSF's expertise in neuroscience and Roche's therapeutic capabilities (Roche Press Release, 2025).
• In April 2025, Eli Lilly and Company completed the acquisition of Prevail Therapeutics, a clinical-stage gene therapy company focused on neurodegenerative diseases, including Parkinson's disease. The acquisition was valued at approximately USD1.1 billion, expanding Eli Lilly's presence in the neurodegenerative disease space (Eli Lilly Press Release, 2025).
• In May 2025, the European Commission approved the use of Vyepti (eptinezumab) for the preventive treatment of cluster headaches in adults. This approval marked the first-ever treatment for cluster headaches in Europe, opening a new chapter in the market (European Commission Press Release, 2025).

Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Dementia And Movement Disorder Treatment Market insights. See full methodology.

Request Free Sample

Research Analyst Overview

• The dementia and movement disorder treatment landscape is characterized by a dynamic and evolving research landscape, with ongoing efforts to address the complexities of Alzheimer's disease progression and various movement disorders. One significant area of focus is the classification and quantification of gait disturbances and neuropsychological testing to better understand disease manifestations. Phase 3 clinical trials are a crucial part of the drug development pipeline, with numerous candidates targeting neurotransmitter imbalance, oxidative stress reduction, and cholinergic system modulation. For instance, researchers are exploring gene expression profiling and protein aggregation pathways to evaluate medication efficacy and patient stratification methods. Neuroinflammation markers, synaptic plasticity enhancement, and tau protein levels are among the key metrics used to assess treatment response and disease progression.
• Neuroimaging modalities, such as functional MRI analysis and PET scan interpretation, play a pivotal role in disease monitoring and diagnosis. Disease symptom management remains a priority, with neuroprotective strategies, pharmacokinetic studies, and neurological examination techniques being employed to mitigate motor skill deterioration and cell death mechanisms. Furthermore, researchers are investigating neuroinflammation markers and dopamine pathway dysfunction to develop novel therapeutic approaches. In the realm of Alzheimer's disease, researchers are actively exploring neurotransmitter imbalance, acetylcholine receptor activity, and cognitive decline metrics. Amyloid beta plaques and tau protein levels are critical biomarkers in disease progression, and understanding their role in disease development is essential for developing effective therapeutic interventions.
• Overall, the market is marked by continuous innovation and a growing understanding of the underlying disease mechanisms. This knowledge drives the development of new therapeutic approaches and diagnostic tools, ultimately improving patient care and outcomes.

What are the Key Data Covered in this Dementia And Movement Disorder Treatment Market Research and Growth Report?

• What is the expected growth of the Dementia And Movement Disorder Treatment Market between 2025 and 2029?

  • USD 14.43 billion, at a CAGR of 9%

• What segmentation does the market report cover?

  • The report segmented by Application (Movement disorders, Progressive dementia, and Progressive dementia with neurological abnormality (PDNA)), Drug Class (MAO inhibitors, Acetylcholinesterase inhibitors, Glutamate inhibitors, and Others), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), and Geography (North America, Europe, Asia, and Rest of World (ROW))

• Which regions are analyzed in the report?

  • North America, Europe, Asia, and Rest of World (ROW)

• What are the key growth drivers and market challenges?

  • Growing geriatric population, High cost of neurological disorders treatment

• Who are the major players in the Dementia And Movement Disorder Treatment Market?

  • Key Companies AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson Services Inc., Kirin Holdings Co. Ltd., Lannett Co Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA

Market Research Insights

• The market encompasses a range of interventions aimed at managing the complex symptoms and care needs of individuals diagnosed with these conditions. According to recent estimates, over 50 million people worldwide live with dementia, with numbers projected to increase by 35% by 2030. Movement disorders, such as Parkinson's disease, affect an additional 7-10 million people globally. Outcome measures selection plays a crucial role in evaluating the effectiveness of various treatment approaches. Statistical modeling and behavioral management strategies, including social support networks, long-term care planning, and caregiver burden evaluation, are essential components of comprehensive care plans. Disease-modifying therapies, neuroprotective agents, and symptomatic treatments, such as occupational therapy techniques, speech therapy approaches, and palliative care options, are among the key interventions in this market.
• Adverse event monitoring and patient safety protocols are essential to ensure the safety and well-being of patients undergoing treatment. Regulatory guidelines and informed consent procedures are integral to the clinical trial design process, enabling the development and approval of innovative therapies. Ethical considerations and end-of-life care are also critical aspects of the dementia and movement disorder treatment landscape. Approximately 13 million family caregivers in the US provide unpaid care to individuals with Alzheimer's or other dementias, saving an estimated USD500 billion in costs annually. In contrast, the global market for disease-modifying therapies for Alzheimer's disease is projected to reach USD33 billion by 2027, highlighting the significant investment required to address the unmet needs of this population.

We can help! Our analysts can customize this dementia and movement disorder treatment market research report to meet your requirements.

Get in touch